Slaughter and May advised Mylan, Inc., the global generic and specialty pharmaceutical company, on its acquisition of Agila Specialties Private Limited, a developer, manufacturer and marketer of high quality generic injectable products from Strides Arcolab Limited for US$1.6 billion in cash. Agila, headquartered in Bangalore, India will bring Mylan a broad product portfolio of more than 300 filings approved globally and marketed through a network covering 70 countries.

The acquisition was announced on 27 February 2013 and is expected to complete in the fourth quarter of 2013.

Slaughter and May advised Mylan, Inc. alongside Skadden, Arps, Slate Meagher & Flom LLP acting as overall legal adviser and Platinum Partners.
 
Contacts

Corporate and Commercial: Gary Eaborn (partner)

http://www.slaughterandmay.com/news-and-recent-work/recent-work/recent-…